The OPTIMA trial, a large international RCT of 4,429 patients aged 40+ with hormone-receptor-positive, node-positive early breast cancer, demonstrates that Prosigna genomic testing can safely de-escalate chemotherapy in 68% of cases with low scores (≤60), yielding 5-year outcomes statistically equivalent to standard chemo-hormone therapy within a prespecified 3% non-inferiority margin. This RCT design, far stronger than observational cohorts, directly targets overtreatment burdens highlighted in editorial priorities, including cardiotoxicity, neuropathy, and quality-of-life erosion that persist even when recurrence risk reduction is marginal. Unlike TAILORx (NEJM 2018, n=10,273, node-negative focus), OPTIMA extends genomic guidance to higher-risk node-positive disease, yet coverage overlooks downstream NHS lab integration advantages of Prosigna versus centralized assays like Oncotype DX. A 2023 Lancet Oncology meta-analysis of precision de-escalation trials (including MINDACT) notes consistent 30-40% chemo avoidance without survival compromise, but flags understudied long-term survivorship data and potential industry conflicts—Veracyte's test role here warrants scrutiny absent in the source. Missed angles include projected annual cost savings exceeding £50 million in the UK alone from reduced infusions, plus equity implications for Thailand and Australia trial sites where access disparities could widen. Precision oncology progress, often eclipsed by novel agents, gains traction through such biology-driven RCTs rather than incremental drug approvals.